Did you know that a subset of patients with microsatellite-stable (MSS) colon cancer have POLE/POLD1 mutations that are associated with high clinical response to immunotherapy?
Join us for this molecular tumor board where we reviewed a case of metastatic MSS-colon cancer with a POLE mutation and high tumor mutational burden, detected on a comprehensive genomic and immune profiling (CGIP) platform. We discuss the incidence and therapeutic significance of POLE/POLD1 proofreading deficiency mutations in patients with colon cancer.
